Loading clinical trials...
Loading clinical trials...
A Randomised, Double-blind, Placebo-controlled, Dose Ascending, 2-cohort, Parallel Group Study to Examine the Safety, Tolerability and Pharmacokinetics of Once-daily Inhaled Doses of GSK573719 Formulated With the Excipient Magnesium Stearatein COPD Subjects for 7 Days
Conditions
Interventions
GSK573719
Locations
7
United Kingdom
GSK Investigational Site
Reading, Berkshire, United Kingdom
GSK Investigational Site
Buckshaw Village, Chorley, Lancashire, United Kingdom
GSK Investigational Site
Waterloo, Liverpool, Merseyside, United Kingdom
GSK Investigational Site
Clydebank, Glasgow, United Kingdom
GSK Investigational Site
Edgbaston, Birmingham, United Kingdom
GSK Investigational Site
Llanishen, United Kingdom
Start Date
October 1, 2008
Primary Completion Date
August 1, 2009
Completion Date
August 1, 2009
Last Updated
November 23, 2016
NCT06831994
NCT02755974
NCT05050591
NCT05913765
NCT05592847
NCT00683722
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions